Actor Michael J. Fox has Parkinson's disease and his foundation's efforts to fight the disease will translate into $468,000 for QR Pharma, a Berwyn start up, according to the company.
QR Pharma, Inc. is a clinical stage specialty pharmaceutical company trying to develop drugs to treat Alzheimer’s disease, Parkinson’s disease and other neurodegenerative disorders.
The Michael J. Fox Foundation for Parkinson’s Research gave QR Pharma the money to conduct research for the development of a drug called Posiphen to treat Parkinson's.
QR says it will collaborate with Dr. Robert Nussbaum, a professor in the genetics department at the University of California, San Francisco, and Jack T. Rogers, an associate professor of psychiatry (neuroscience) in the genetics and aging research unit at Massachusetts General Hospital.
“We are pleased that The Michael J. Fox Foundation for Parkinson’s Research sees the potential of Posiphen in the treatment of Parkinson’s disease,” Maria Maccecchini, QR Pharma's chief executive officer, said in a statement. “We look forward to working with the excellent research teams led by Dr. Nussbaum and Dr. Rogers.”